Livingston Group Asset Management CO operating as Southport Capital Management increased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 4.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,649 shares of the biopharmaceutical company’s stock after acquiring an additional 316 shares during the quarter. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Bristol-Myers Squibb were worth $491,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Garrett Wealth Advisory Group LLC acquired a new stake in Bristol-Myers Squibb during the third quarter worth about $26,000. Lenox Wealth Advisors LLC grew its stake in Bristol-Myers Squibb by 555.7% during the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 539 shares in the last quarter. Financial Gravity Wealth Inc. grew its stake in Bristol-Myers Squibb by 101.2% during the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 327 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in Bristol-Myers Squibb by 52.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 230 shares in the last quarter. Finally, 1 North Wealth Services LLC acquired a new stake in Bristol-Myers Squibb during the third quarter worth about $41,000. 83.02% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider Louis S. Schmukler sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the transaction, the insider now owns 31,963 shares of the company’s stock, valued at $1,807,827.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John E. Elicker sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total transaction of $849,900.00. Following the transaction, the senior vice president now directly owns 74,471 shares of the company’s stock, valued at approximately $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by company insiders.

Several research analysts have recently issued reports on BMY shares. Bank of America initiated coverage on shares of Bristol-Myers Squibb in a report on Wednesday, October 16th. They set a “buy” rating and a $60.00 price target for the company. Gabelli assumed coverage on Bristol-Myers Squibb in a report on Wednesday, November 27th. They set a “buy” rating on the stock. Morgan Stanley assumed coverage on Bristol-Myers Squibb in a research report on Friday, November 22nd. They set an “equal weight” rating and a $60.00 price objective on the stock. TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Finally, Mizuho initiated coverage on Bristol-Myers Squibb in a research report on Monday, November 25th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $61.69.

Shares of BMY stock traded up $0.10 during trading hours on Thursday, hitting $66.68. 3,255,733 shares of the company’s stock traded hands, compared to its average volume of 12,465,342. The stock’s 50 day simple moving average is $62.52 and its 200 day simple moving average is $53.03. The stock has a market cap of $108.25 billion, a PE ratio of 16.75, a price-to-earnings-growth ratio of 0.85 and a beta of 0.73. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $67.09. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.11. The firm had revenue of $6.01 billion during the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.09 earnings per share. As a group, equities research analysts expect that Bristol-Myers Squibb Co will post 4.47 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a dividend of $0.45 per share. The ex-dividend date is Thursday, January 2nd. This represents a $1.80 annualized dividend and a dividend yield of 2.70%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 45.23%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: What Are Cryptocurrencies?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.